- Samsung (KS:) Biology to Aqaba Development Company presentation Services in a new dedicated facility
- The expanded collaboration reflects the successful partnership and experience
Incheon,
Samsung Biology It will support a series of ADCs from LigaChem Biosciences Programs in Samsung Biologics New custom ADC facility. The two companies have already collaborated on ADC programs for the treatment of solid tumors. LigaChem Biosciences is a leading biotechnology company in the research and development of ADC candidates.
“The recent cooperation will be further strengthened Samsung Biologics “Capabilities are at all stages of ADC development and manufacturing as part of our commitment to providing safe, high-quality treatments to patients,” he said.
“This collaboration with Samsung Biologics “It will be an important step towards strengthening the supply chain of high-quality ADC medicines and enhancing the competitiveness of both companies in the global ADC market.”
Samsung Biologics The ADC facility is a separate wing, equipped with a 500 L reactor, that supports the development and manufacturing of ADC therapeutics. Building on the company's track record of experience in large-scale antibody manufacturing and process engineering, Samsung Biologics The scope of ADC service extends from late detection to development and correlationon me.
Samsung Biologics Active investments were also made through Samsung life (KS:) Science Fund At biotechnology companies leading ADC linker technologies, toolbox and protein engineering.
For more information, visit: https://samsungbiologics.com/services/adc
on SAMSUNG BIOLOGICS CO., LTD
Samsung Biologics (KRX: 207940.KS) is a fully integrated CDMO provider, offering seamless development and manufacturing solutions from cell line development to sterile filling/finishing as well as laboratory testing support for the biopharmaceutical products we manufacture. Our state-of-the-art facilities are CGMP compliant with bioreactors ranging from small to large scales to serve diverse customer needs. Maximize operational efficiency and expand our capabilities in response to the growing demand for biomanufacturing, Samsung Biologics The company offers a total capacity of 604 KL at Bio Campus I. The company launched Bio Campus II with the construction of Plant 5, which will be commissioned in April 2025, adding a biomanufacturing capacity of 180 KL. Additionally, Samsung Biologics America enables the company to operate in close proximity to customers residing in
About LigaChem Biosciences
Liga Chem Biosciences Inc (LCB) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative medicines by leveraging medicinal chemistry expertise to make conventional biologics more targeted and effective to benefit patients with diseases with largely unmet medical needs. LCB develops sustainable pipelines in therapeutic areas within the antibiotic, antineoplastic, and ADC platform. For more information, visit https://ligachembio.com/
Contact Samsung Biologics
cair.kim@samsung.com
Contact LigaChem Biosciences
jdy@ligachembio.com
